Low TML, rare PD‐L1 expression (1/6 TC+ and 3/5 IC+), and absence of mismatch repair deficiency make this tumor an inconsistent candidate for treatment with the current immune checkpoint inhibitors.5 We encourage further studies on PDC to reveal novel predictive biomarkers for this rare and difficult‐to‐treat breast cancer subtype. This evidence concerns the gene CD274 and neoplasm.